Led Typewriter Therapeutics' $56M Series A as the company emerged from stealth with an RNA-based, non-viral in vivo gene insertion platform.
Typewriter Therapeutics is a biotech company developing safe, durable, and re-dosable genetic medicines with curative impact for patients with cancer, autoimmune diseases, and severe genetic diseases
Typewriter Therapeutics is a biotech company developing safe, durable, and re-dosable genetic medicines with curative impact for patients with cancer, autoimmune diseases, and severe genetic diseases. Their platform utilizes a non-viral approach to insert therapeutic genes into the genome using lipid nanoparticle-delivered RNA.